Portfolio

BaroSense, Inc.

Menlo Park, CA
barosense.com

About BaroSense:

Founded in 2001, BaroSense is focused on a minimally invasive device-based treatment for obesity. Obesity is the second leading cause of unnecessary deaths in the US. BaroSense has assembled thought leaders from gastroenterology, bariatric surgery, endocrinology, and interventional cardiology to tackle the growing epidemic of obesity. BaroSense was financed in June 2002 by Synecor’s Venture Partners, Delphi Ventures and Frazier Healthcare.

BioStent, Inc./Bioerodible Vascular Solutions

Mountain View, CA
abbottvascular.com

About BioStent:

Founded in 2002, and acquired by Guidant/Abbott in 2004 BioStent was formed to develop fully bioerodible vascular stent platforms for the restoration of blood flow in patients with Coronary Artery Disease. Drug-eluting bioerodible stents represent an entirely new frontier in vascular intervention. Decades of interventional cardiology and biomaterials expertise laid the foundation for this novel technology. BVS recently announced the results of a successful 60 patient first in man trial outside the US at the October 2006 TCT conference.

InnerPulse, Inc.

Research Triangle Park, NC
inner-pulse.com

About Inner-Pulse:

InnerPulse was founded in 2003 and incubated by Synecor LLC to focus on the management of patients with arrhythmias, or abnormal heart rhythms. Synecor LLC is an accelerator of innovative medical technology with offices located in Research Triangle Park, NC, Portola Valley, CA, and Santa Rosa, CA. Synecor has assembled significant scientific, financial, and corporate partnerships that participate in the Synecor incubation model.

TransEnterix, Inc.

Research Triangle Park, NC

About TransEnterix:

Founded in 2006, TransEnterix, is pioneering technology in the area of "incisionless" surgery. TransEnterix is developing a disruptive technology platform to access and treat the patient's GI system entirely through a natural orifice. The Principals envision a future of indications that would be performed trans-orally accessing the area of interest via the mouth and through the stomach wall as well as other natural entry points. The company has made substantial progress in developing a single port system that can replicate many of the current Laparoscopic procedures that currently requre multiple puncture sites. Lower morbidity, faster full recovery and an improved cosmetic result are a few of the salient advantages that the firm plans to realize.